MediciNova Beheer
Beheer criteriumcontroles 2/4
De CEO MediciNova is Yuichi Iwaki, benoemd in Jan2000, heeft een ambtstermijn van 24.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.39M, bestaande uit 47.4% salaris en 52.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 2.23% van de aandelen van het bedrijf, ter waarde $ 1.70M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 8.3 jaar en 5.3 jaar.
Belangrijke informatie
Yuichi Iwaki
Algemeen directeur
US$1.4m
Totale compensatie
Percentage CEO-salaris | 47.4% |
Dienstverband CEO | 24.8yrs |
Eigendom CEO | 2.2% |
Management gemiddelde ambtstermijn | 8.3yrs |
Gemiddelde ambtstermijn bestuur | 5.3yrs |
Recente managementupdates
Recent updates
Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth
Aug 28We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely
Apr 19MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans
Nov 27We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely
Jul 11Here's Why We're Not Too Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Situation
Mar 18We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth
Oct 12MediciNova to get US patent for MN-166 to treat brain cancer
Sep 15MediciNova's MN-166 to be part of study to treat Long COVID
Aug 16MediciNova begins study of parenteral formulation of MN-166
Jul 22MediciNova announces extension of BARDA contract for Ibudilast development
Jun 30We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely
Mar 19MediciNova (NASDAQ:MNOV) Is In A Strong Position To Grow Its Business
Nov 23MediciNova: The Pain Of A Positive Outlook
Aug 31MediciNova stock climbs 31% on positive MN-166 data in mid-stage alcohol use disorder study
Jun 21Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth
May 15The MediciNova Riddle: Worth Unravelling
Apr 26MediciNova inks $20M securities purchase agreement with 3D Investment Partners
Jan 12MediciNova nabs new U.S. patent for ibudilast in multiple sclerosis
Dec 29MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans
Dec 29Analyse CEO-vergoeding
Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$8m |
Mar 31 2024 | n/a | n/a | -US$8m |
Dec 31 2023 | US$1m | US$657k | -US$9m |
Sep 30 2023 | n/a | n/a | -US$10m |
Jun 30 2023 | n/a | n/a | -US$12m |
Mar 31 2023 | n/a | n/a | -US$14m |
Dec 31 2022 | US$1m | US$620k | -US$14m |
Sep 30 2022 | n/a | n/a | -US$13m |
Jun 30 2022 | n/a | n/a | -US$13m |
Mar 31 2022 | n/a | n/a | -US$13m |
Dec 31 2021 | US$3m | US$596k | -US$10m |
Sep 30 2021 | n/a | n/a | -US$11m |
Jun 30 2021 | n/a | n/a | -US$11m |
Mar 31 2021 | n/a | n/a | -US$11m |
Dec 31 2020 | US$3m | US$587k | -US$14m |
Sep 30 2020 | n/a | n/a | -US$13m |
Jun 30 2020 | n/a | n/a | -US$12m |
Mar 31 2020 | n/a | n/a | -US$11m |
Dec 31 2019 | US$4m | US$572k | -US$13m |
Sep 30 2019 | n/a | n/a | -US$11m |
Jun 30 2019 | n/a | n/a | -US$16m |
Mar 31 2019 | n/a | n/a | -US$15m |
Dec 31 2018 | US$3m | US$551k | -US$15m |
Sep 30 2018 | n/a | n/a | -US$16m |
Jun 30 2018 | n/a | n/a | -US$13m |
Mar 31 2018 | n/a | n/a | -US$13m |
Dec 31 2017 | US$3m | US$534k | -US$11m |
Compensatie versus markt: De totale vergoeding ($USD 1.39M ) Yuichi } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 651.15K ).
Compensatie versus inkomsten: De vergoeding van Yuichi is gestegen terwijl het bedrijf verliesgevend is.
CEO
Yuichi Iwaki (74 yo)
24.8yrs
Tenure
US$1,388,309
Compensatie
Dr. Yuichi Iwaki, M.D., Ph D., is a Co-Founder of MediciNova Inc. and has been its Chief Executive Officer and President since March 2006. Dr. Iwaki served as Acting Principal Financial Officer at MediciNo...
Leiderschapsteam
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
Co-Founder | 24.8yrs | US$1.39m | 2.23% $ 1.7m | |
Chief Medical Officer & Director | 13.2yrs | US$1.01m | 0.66% $ 503.9k | |
CFO & Principal Financial Officer | 2.4yrs | geen gegevens | geen gegevens | |
Chief Business Officer | 3.5yrs | geen gegevens | geen gegevens | |
Controller | no data | geen gegevens | geen gegevens |
8.3yrs
Gemiddelde duur
58.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van MNOV is doorgewinterd en ervaren (gemiddelde ambtstermijn van 8.3 jaar).
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
Co-Founder | 24.2yrs | US$1.39m | 2.23% $ 1.7m | |
Chief Medical Officer & Director | 5.3yrs | US$1.01m | 0.66% $ 503.9k | |
Independent Director | 7yrs | US$69.23k | 0% $ 0 | |
Independent Director | 4.1yrs | US$69.23k | 0% $ 0 | |
Independent Director | 1.3yrs | US$46.16k | 0% $ 0 |
5.3yrs
Gemiddelde duur
66yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van MNOV wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.3 jaar).